Lucentis and Cfa - a phase IV clinical study of FDA data

Summary:

Cfa is reported as a side effect among people who take Lucentis (ranibizumab), especially for people who are male, 60+ old, also take Tamsulosin, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Cfa when taking Lucentis. It is created by eHealthMe based on reports of 25,577 people who have side effects when taking Lucentis from the FDA, and is updated regularly.

What is Lucentis?

Lucentis has active ingredients of ranibizumab. It is often used in macular degeneration. eHealthMe is studying from 25,647 Lucentis users. Check the latest studies of Lucentis.

What is Cfa?

Cfa is found to be associated with 1,984 drugs and 2,268 conditions by eHealthMe. Check the latest studies of Cfa.

On Apr, 09, 2026

25,577 people reported to have side effects when taking Lucentis.
Among them, 23 people (0.09%) have Cfa.

Among these 23 people:

What is the gender of people who have Cfa when taking Lucentis? *

female: 23.81 %
male: 76.19 %

What is the age of people who have Cfa when taking Lucentis? *

What are other drugs people take besides Lucentis? *

What are other side effects people have besides Cfa? *

General Physical Health Deterioration (weak health status): 9 people, 39.13%
Fall: 9 people, 39.13%
Mobility Decreased (ability to move is reduced): 6 people, 26.09%
Abnormal Loss Of Weight: 5 people, 21.74%
Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 5 people, 21.74%
Oedema Peripheral (superficial swelling): 3 people, 13.04%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 13.04%
Nasopharyngitis (inflammation of the nasopharynx): 2 people, 8.70%
Interstitial Lung Disease: 2 people, 8.70%
Injection Site Pain: 2 people, 8.70%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 7 people, 30.43%
Retinal Vessel Occlusion (a blockage in one of the small arteries): 2 people, 8.70%
Lung Disorder (lung disease): 2 people, 8.70%
Maculopathy (a condition or disease of the macula, the small spot in the retina where vision is keenest): 1 person, 4.35%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 1 person, 4.35%
High Blood Pressure: 1 person, 4.35%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 4.35%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 1 person, 4.35%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 4.35%
Asthma: 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Lucentis and have Cfa?

- Check whether Cfa is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lucentis:

Lucentis (25,647 reports)

Cfa treatments and more:

Cfa (79,194 reports)

Browse all side effects of Lucentis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cfa:

Cfa (1,984 drugs)

Browse all the conditions that are associated with Cfa:

Cfa (2,268 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ranibizumab (the active ingredients of Lucentis) and Lucentis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.